These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 23899641)

  • 21. A randomized, double-blind, placebo-controlled trial of fluvoxamine in patients with schizophrenia: a preliminary study.
    Niitsu T; Fujisaki M; Shiina A; Yoshida T; Hasegawa T; Kanahara N; Hashimoto T; Shiraishi T; Fukami G; Nakazato M; Shirayama Y; Hashimoto K; Iyo M
    J Clin Psychopharmacol; 2012 Oct; 32(5):593-601. PubMed ID: 22926591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The onset and time course of response of negative symptoms to add-on fluvoxamine treatment.
    Silver H; Nassar A; Aharon N; Kaplan A
    Int Clin Psychopharmacol; 2003 Mar; 18(2):87-92. PubMed ID: 12598819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics.
    Reznik I; Sirota P
    J Clin Psychopharmacol; 2000 Aug; 20(4):410-6. PubMed ID: 10917401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melatonin secretion during fluvoxamine treatment in medicated chronic schizophrenic patients: evidence for the development of tolerance to selective serotonin re-uptake inhibitor.
    Silver H; Barash I; Odnopozov N; Jahjah N; Mizruhin A
    Biol Psychiatry; 1996 Jul; 40(1):75-7. PubMed ID: 8780859
    [No Abstract]   [Full Text] [Related]  

  • 25. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
    Dwivedi S; Pavuluri M; Heidenreich J; Wright T
    J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
    [No Abstract]   [Full Text] [Related]  

  • 26. [SSRI antidepressants and negative schizophrenic symptoms: differences between paroxetine and fluvoxamine in patients treated with olanzapine].
    Rusconi AC; Carlone C; Muscillo M; Coccanari de' Fornari MA; Podda L; Piccione M
    Riv Psichiatr; 2009; 44(5):313-9. PubMed ID: 20066819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacotherapy of chronic schizophrenic psychoses--neuroleptic plus serotonin reuptake inhibitor?].
    Salzmann E; Eikelmann B
    Psychiatr Prax; 1997 Sep; 24(5):253. PubMed ID: 9417552
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful treatment of Meige's syndrome induced by risperidone and fluvoxamine with olanzapine monotherapy in schizophrenia.
    Miyamoto S; Miyake N; Ogino S; Endo T; Yamaguchi N
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):702-3. PubMed ID: 18081639
    [No Abstract]   [Full Text] [Related]  

  • 29. The involvement of BDNF-CREB signaling pathways in the pharmacological mechanism of combined SSRI- antipsychotic treatment in schizophrenia.
    Einoch R; Weinreb O; Mandiuk N; Youdim MBH; Bilker W; Silver H
    Eur Neuropsychopharmacol; 2017 May; 27(5):470-483. PubMed ID: 28410959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.
    Uzun O; Ozdemir B
    Clin Drug Investig; 2010; 30(10):707-10. PubMed ID: 20701402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective serotonin reuptake inhibitor (SSRI) add-on therapy for the negative symptoms of schizophrenia: a meta-analysis.
    Sepehry AA; Potvin S; Elie R; Stip E
    J Clin Psychiatry; 2007 Apr; 68(4):604-10. PubMed ID: 17474817
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin reuptake inhibitor treatment of obsessive-compulsive symptoms in clozapine-medicated schizophrenia.
    Andrade C
    J Clin Psychiatry; 2012 Nov; 73(11):e1362-4. PubMed ID: 23218164
    [No Abstract]   [Full Text] [Related]  

  • 33. Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study.
    Silver H; Kushnir M; Kaplan A
    Biol Psychiatry; 1996 Oct; 40(7):671-4. PubMed ID: 8886304
    [No Abstract]   [Full Text] [Related]  

  • 34. Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials.
    Kishi T; Hirota T; Iwata N
    Eur Arch Psychiatry Clin Neurosci; 2013 Dec; 263(8):633-41. PubMed ID: 23605347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features.
    Strous RD; Patel JK; Zimmet S; Green AI
    Am J Psychiatry; 1999 Jun; 156(6):973-4. PubMed ID: 10360153
    [No Abstract]   [Full Text] [Related]  

  • 36. An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.
    Reznik I; Sirota P
    Clin Neuropharmacol; 2000; 23(3):157-60. PubMed ID: 10895399
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluvoxamine as an adjunctive agent in schizophrenia.
    Silver H
    CNS Drug Rev; 2001; 7(3):283-304. PubMed ID: 11607044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Obsessive-compulsive disorder and schizophrenia].
    Denda K
    Ryoikibetsu Shokogun Shirizu; 2003; (38):459-63. PubMed ID: 12877026
    [No Abstract]   [Full Text] [Related]  

  • 39. Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study.
    Wetzel H; Anghelescu I; Szegedi A; Wiesner J; Weigmann H; Härter S; Hiemke C
    J Clin Psychopharmacol; 1998 Feb; 18(1):2-9. PubMed ID: 9472836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study.
    Poyurovsky M; Isakov V; Hromnikov S; Modai I; Rauchberger B; Schneidman M; Weizman A
    Int Clin Psychopharmacol; 1999 Mar; 14(2):95-100. PubMed ID: 10220124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.